IPG-CANDESARTAN TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CANDESARTAN CILEXETIL

Предлага се от:

MARCAN PHARMACEUTICALS INC

АТС код:

C09CA06

INN (Международно Name):

CANDESARTAN

дозиране:

32MG

Лекарствена форма:

TABLET

Композиция:

CANDESARTAN CILEXETIL 32MG

Начин на приложение:

ORAL

Броя в опаковка:

30/1000

Вид предписание :

Prescription

Терапевтична област:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Каталог на резюме:

Active ingredient group (AIG) number: 0135220004; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2016-08-19

Данни за продукта

1
PRODUCT MONOGRAPH
PR
IPG-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Date of Preparation:
August 19, 2016
Marcan Pharmaceuticals Inc.
77 Auriga Drive, Suite #4
Ottawa, Ontario
K2E 7Z7
CONTROL# 196962
2
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................................
3
SUMMARY PRODUCT INFORMATION
........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................................
8
DRUG INTERACTIONS
...............................................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................................................
17
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................................................
20
STORAGE AND
STABILITY..........................................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................................
23
PART II: SCIENTIFIC INFORMATION
.....................